Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma (ASND) Form 144 filing: the filing dated 03/02/2026 lists a planned sale of ordinary shares through Citigroup Global Markets as broker. The filing also records a prior disposition of 10,000 ordinary shares on 12/04/2025 with proceeds of 2,081,018.69. The notice notes restricted stock vesting dated 03/02/2026 in connection with compensation.
Ascendis Pharma A/S submitted a Form 144 disclosing the proposed sale of 10,800 ordinary shares through Citigroup Global Markets on 03/02/2026. The filing also records restricted stock vesting of 18,349 shares as compensation on 03/02/2026 and prior sales of 10,000 shares on 12/02/2025 for 2093222.47.
Ascendis Pharma A/S reported a proposed sale of 10,800 ordinary shares via Citigroup Global Markets on 03/02/2026. The filing also shows 18,349 restricted shares vesting on 03/02/2026 as compensation, and discloses 10,000 shares sold on 12/02/2025 for $2,058,454.18.
Ascendis Pharma A/S reports that the U.S. FDA has granted Accelerated Approval to YUVIWEL (navepegritide; TransCon CNP), the first and only once-weekly treatment to increase linear growth in children 2 years and older with achondroplasia and open epiphyses. YUVIWEL is a prodrug of C‑type natriuretic peptide designed to provide continuous systemic exposure over the weekly dosing interval.
The approval is based on improved annualized growth velocity and is subject to confirmation of clinical benefit in ongoing or future trials. Ascendis plans to make YUVIWEL available in the United States in the early part of the second quarter of 2026 and to support patients through its Ascendis Signature Access Program with treatment navigation and financial assistance services.
With this decision, the FDA also issued Ascendis a Rare Pediatric Disease Priority Review Voucher, which can grant priority review to a future drug application and reflects the rare pediatric nature of achondroplasia.
Ascendis Pharma A/S furnished a Form 6-K providing notice of its March 23, 2026 annual general meeting and attaching its audited 2025 annual report and sustainability report. For 2025, revenue rose to €720.1 million, while the consolidated loss was €228.0 million, which the board proposes to carry forward.
Operating loss improved to €136.3 million, net finance expenses were €92.7 million, and cash and cash equivalents reached €616.0 million with total assets of €1.30 billion. The company reports continued commercial growth of YORVIPATH and SKYTROFA, advances in its TransCon pipeline in endocrinology and oncology, and new strategic collaborations, including a major TransCon semaglutide partnership with Novo Nordisk and regional deals with Teijin, VISEN and Eyconis.